{
    "clinical_study": {
        "@rank": "4778", 
        "arm_group": [
            {
                "arm_group_label": "Vitamin D3 2000 IU", 
                "arm_group_type": "Active Comparator", 
                "description": "Vitamin D3 2000 IU tablet once daily by mouth for 6 months"
            }, 
            {
                "arm_group_label": "Vitamin D3 1000 IU", 
                "arm_group_type": "Active Comparator", 
                "description": "Vitamin D3 1000 IU tablet by mouth once daily for 6 months"
            }, 
            {
                "arm_group_label": "Vitamin D3 600 IU", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vitamin D3 600 IU tablet by mouth once daily for 6 months"
            }
        ], 
        "brief_summary": {
            "textblock": "In this study, we will test the central hypothesis that enhancement of vitamin D status in\n      obese and overweight children will improve their vascular health and their cardiovascular\n      disease (CVD) and metabolic syndrome risk profile."
        }, 
        "brief_title": "Vitamin D and Vascular Health in Children", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Obesity", 
            "Vitamin D Deficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Vitamin D Deficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "Our primary objective is to determine, in obese and overweight children aged 10 to 18 years\n      with vitamin D deficiency (defined as serum 25-hydroxyvitamin D <20 ng/mL), the efficacy of\n      enhanced vitamin D3 supplementation in improving vascular endothelial function, arterial\n      stiffness, insulin sensitivity, and metabolic syndrome risk status; and to assess whether\n      these effects are dose-dependent. As a secondary objective, we will examine the vitamin D\n      supplementation-induced effect on adipokines and inflammatory markers relevant to CVD risk.\n      In a double-masked, controlled trial, we will randomize 252 eligible children to receive\n      either 600 IU (conventional supplementation), or 1000 IU or 2000 IU (enhanced\n      supplementation) of vitamin D3 daily for 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Eligible subjects will be 10 to 18 years of age;\n\n          -  obese or overweight (BMI \u226585th %tile);\n\n          -  otherwise healthy, and\n\n          -  have a serum 25(OH)D concentration <20 ng/mL\n\n        Children taking multivitamins should be able to hold off their multivitamins during the\n        course of the study.\n\n        Exclusion Criteria:\n\n        Children will be excluded if they\n\n          -  (a) have hepatic or renal disease, metabolic rickets, malabsorptive disorders,\n             primary hyperparathyroidism, hyperthyroidism, or other chronic disorders that could\n             affect vitamin D metabolism;\n\n          -  (b) are receiving treatment with anticonvulsants, systemic glucocorticoids,\n             pharmacologic doses of vitamin D (\u22651000 IU of vitamin D2 or D3 daily),\n             antihypertensives, vasoactive drugs, antilipidemics, metformin, antipsychotics, or\n             other oral insulin regulators;\n\n          -  (c) have cholelithiasis or urolithiasis;\n\n          -  (d) have type 1 or type 2 diabetes; or\n\n          -  (e) have a condition or underlying abnormality that could compromise the safety of\n             the subject.\n\n        Post-menarchial girls with a positive pregnancy test at randomization, or subjects found\n        during the screening phase to have hypercalcemia (serum calcium >10.8 mg/dL) or\n        significant fasting hyperglycemia (fasting blood glucose \u2265 125 mg/dL) will also be\n        excluded."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "18 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "252", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01797302", 
            "org_study_id": "PRO12100034", 
            "secondary_id": "R01HL112985"
        }, 
        "intervention": {
            "arm_group_label": [
                "Vitamin D3 2000 IU", 
                "Vitamin D3 1000 IU", 
                "Vitamin D3 600 IU"
            ], 
            "description": "Tablet form", 
            "intervention_name": "Vitamin D3", 
            "intervention_type": "Dietary Supplement", 
            "other_name": "Cholecalciferol"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Obesity", 
            "Vitamin D Deficiency", 
            "Vascular Function", 
            "Insulin resistance", 
            "metabolic syndrome"
        ], 
        "lastchanged_date": "August 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15213"
                }, 
                "name": "Primary Care Center, Children's Hospital of Pittsburgh of UPMC"
            }, 
            "investigator": {
                "last_name": "Kumaravel Rajakumar, MD, MS", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Vitamin D and Vascular Function in Obese Children", 
        "other_outcome": [
            {
                "description": "components of metabolic syndrome", 
                "measure": "blood pressure, waist circumference, HDL cholesterol, triglycerides, and fasting blood glucose", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "inflammatory markers", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "adipokines", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "nitric oxide metabolites", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "overall_contact": {
            "email": "flora.olabopo@chp.edu", 
            "last_name": "Flora Olabopo, BS", 
            "phone": "412-692-8737"
        }, 
        "overall_contact_backup": {
            "email": "kumaravel.rajakumar@chp.edu", 
            "last_name": "Kumaravel Rajakumar, MD, MS", 
            "phone": "412-692-5415"
        }, 
        "overall_official": {
            "affiliation": "University of Pittsburgh, Children's Hospital of Pittsburgh of UPMC", 
            "last_name": "Kumaravel Rajakumar, MD, MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Data and Safety Monitoring Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "measure of vascular endothelial function", 
            "measure": "brachial artery flow-mediated dilation (FMD)", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01797302"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pittsburgh", 
            "investigator_full_name": "Kumaravel Rajakumar", 
            "investigator_title": "Associate Professor of Pediatrics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "measure of arterial stiffness", 
                "measure": "pulse-wave velocity (PWV)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR) as a surrogate estimate of insulin sensitivity", 
                "measure": "fasting glucose/fasting insulin ratio", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "University of Pittsburgh", 
        "sponsors": {
            "collaborator": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Pittsburgh", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}